Based in Boston and Geneva, Alys Pharmaceuticals is an immuno-dermatology-focused company founded by merging six asset-centric Medicxi companies. Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. Alys has started off with a $100 million investment from Medicxi.
